From: Imputation of missing values of tumour stage in population-based cancer registration
 |  | Breast cancer data set | Malignant melanoma data set | ||
---|---|---|---|---|---|
 |  | Observed | Simulated* | Observed | Simulated* |
Number of cases | Â | 21,428 | 17,162 | 5,520 | 1,685 |
Sex (in %) | Female | 100 | 100 | 45.8 | 45.1 |
 | Male | 0 | 0 | 54.2 | 54.9 |
Age | Median (1st and 3rd Quartile) | 62.0 (53.0; 71.0) | 61.0 (52.0; 69.0) | 61.0 (45.0; 70.2) | 59.0 (43.0; 68.0) |
T-stage (in %) | 1 | 47.3 | 49.2 | 36.9 | 36.9 |
 | 2 | 34.0 | 34.3 | 11.8 | 12.4 |
 | 3 | 5.5 | 5.1 | 8.0 | 7.6 |
 | 4 | 7.3 | 5.7 | 4.7 | 4.4 |
 | Unknown | 6.0 | 5.7 | 38.6 | 38.7 |
N-stage (in %) | 0 | 53.4 | 55.1 | 29.5 | 32.5 |
 | 1 | 25.4 | 25.2 | 1.7 | 1.4 |
 | 2 | 6.1 | 5.9 | 0.6 | 0.4 |
 | 3 | 3.7 | 3.5 | 0.2 | 0.1 |
 | Unknown | 11.4 | 10.3 | 67.9 | 65.6 |
M-stage (in %) | 0 | 77.9 | 80.8 | 31.0 | 33.5 |
 | 1 | 5.6 | 3.7 | 2.2 | 0.7 |
 | Unknown | 16.5 | 15.4 | 66.8 | 65.8 |
UICC-stage (in %) | I | 32.0 | 29.7 | 23.9 | 7.4 |
 | II | 33.2 | 30.0 | 3.3 | 0.7 |
 | III | 11.4 | 10.4 | 2.8 | 0.8 |
 | IV | 5.6 | 3.7 | 0.5 | 0.7 |
 | Unknown | 17.8 | 26.1 | 69.5 | 90.4 |
Survival time (days) | Median (1st and 3rd Quartile) | 1279 (549; 2161) | 1279 (580; 2130) | 1552 (700; 2253) | 1765 (975; 2557) |
Censoring (in %) | Censored | 84.6 | 88.5 | 88.1 | 90.5 |
Year of diagnosis | 2000 | 10.2 | 9.7 | 10.8 | 15.1 |
 | 2001 | 10.7 | 10.2 | 11.5 | 14.4 |
 | 2002 | 11.1 | 10.6 | 10.0 | 10.9 |
 | 2003 | 10.8 | 10.9 | 14.3 | 12.2 |
 | 2004 | 10.7 | 10.7 | 12.8 | 14.6 |
 | 2005 | 10.7 | 10.9 | 10.7 | 8.9 |
 | 2006 | 11.5 | 11.6 | 10.0 | 10.8 |
 | 2007 | 11.6 | 12.1 | 9.7 | 5.0 |
 | 2008 | 12.7 | 13.4 | 10.3 | 8.1 |
Grading (in %) | 1 | 10.6 | 10.6 | 3.4 | 5.7 |
 | 2 | 54.2 | 53.7 | 0.3 | 0.2 |
 | 3 | 30.0 | 30.1 | 0.2 | 0.2 |
 | 4 | 0.2 | 0.1 | < 0.1 | 0.1 |
 | Unknown | 5.0 | 5.5 | 96.1 | 93.8 |
Radiotherapy (in %) | Yes | 66.4 | 80.2 | 1.4 | 0.5 |
 | no | 17.8 | 15.3 | 52.2 | 64.5 |
 | Unknown | 15.8 | 4.5 | 46.4 | 35.0 |
Chemotherapy (in %) | Yes | 46.1 | 47.9 | 1.8 | 1.4 |
 | No | 37.4 | 36.7 | 51.8 | 63.9 |
 | Unknown | 16.6 | 15.5 | 46.5 | 34.8 |
Hormone therapy (in %) | Yes | 60.6 | 62.3 | 0.0 | 0.0 |
 | No | 19.1 | 18.1 |  |  |
 | Unknown | 20.3 | 19.6 |  |  |
Morphology (in %) | Infiltrating duct carcinoma | 69.0 | 70.6 | Â | Â |
 | Lobular carcinoma | 12.3 | 11.9 |  |  |
 | Infiltrating duct and lobular carcinoma | 7.4 | 7.9 |  |  |
 | Nodular melanoma |  |  | 12.4 | 13.6 |
 | Lentigo maligna melanoma |  |  | 5.3 | 5.1 |
 | Superficial spreading melanoma |  |  | 41.4 | 48.4 |
 | Others and NOS | 10.5 | 9.6 | 41.0 | 32.8 |
Topography (in %) | Central portion of breast | 5.3 | 5.1 | Â | Â |
 | Upper-inner quadrant of breast | 9.3 | 9.6 |  |  |
 | Lower-inner quadrant of breast | 4.6 | 4.7 |  |  |
 | Upper-outer quadrant of breast | 35.7 | 36.3 |  |  |
 | Lower-outer quadrant of breast | 6.3 | 6.3 |  |  |
 | Axillary tail of breast | 0.2 | 0.1 |  |  |
 | Overlapping lesion of breast | 8.9 | 8.2 |  |  |
 | Trunc |  |  | 32.2 | 35.9 |
 | Extremity |  |  | 46.7 | 50.1 |
 | Head/Neck |  |  | 13.5 | 11.3 |
 | NOS | 29.9 | 29.7 | 7.6 | 2.7 |